Skip to main content

Table 1 Characteristics of patients in phase 1 and phase 2

From: A prospective evaluation of cardiovascular magnetic resonance measures of dyssynchrony in the prediction of response to cardiac resynchronization therapy

  Phase 1 cohort Phase 2 cohort P value
N 44 50  
Age (years) 63.3 ± 14.1 68.6 ± 12.2 0.06
Sex (male/female) 40/4 35/15 0.01
Etiology 23 DCM 31 DCM 0.34
21 ICM 19 ICM  
Number of patients with scar on CMR n(%) 24 (55) 21 (42) 0.22
Scar burden on CMR in those patients with scar (% of myocardium) 21.4 ± 7.9 24.4 ± 11.4 0.35
QRS duration (ms) 154 ± 24 146 ± 21 0.11
QRS morphology (LBBB/RBBB/IVCD) 31/5/8 28/4/18 0.15
Rhythm 38 SR 42 SR 0.53
6 AF 8 AF  
Beta blockers n(%) 40 (91) 38 (76) 0.11
ACEI/ARB n(%) 43 (98) 49 (98) 0.84
Diuretics n(%) 27 (62) 35 (70) 0.44
Aldosterone antagonists n(%) 17 (38) 33 (66) 0.27
NYHA class n(%)    
II 7 (16) 12 (24) 0.23
III 35 (80) 38 (76)  
IV 2 (4) 0  
QOL score pre CRT 51 ± 24 50 ± 26 0.41
6 minute walk distance (m) 255 ± 112 295 ± 149 0.02
Ejection fraction (%)* 25 ± 9 22 ± 9 0.14
End diastolic volume (ml)* 232 ± 72 218 ± 90 0.43
End systolic volume (ml)* 175 ± 67 172 ± 82 0.88
LV lead position    0.86
Lateral 20 21  
Posterolateral 21 22  
Anterior 3 5  
Posterior 3 2  
LV lead in area with >50% transmural scar n(%) 4(9) 7(14) 0.46
  1. *Volumes and ejection fraction derived from 2D echocardiography.
  2. Abbreviations: CMR cardiovascular magnetic resonance, LBBB left bundle branch block, RBBB right bundle branch block, IVCD non-specific interventricular conduction delay, AF atrial fibrillation, ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, NYHA New York Heart Association, QOL quality of life.